A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label pimavanserin treatment.
Inclusion Criteria:
Exclusion Criteria:
Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.
Aventura, Florida 33180, United States
Boca Raton, Florida 33486, United States
Kansas City, Kansas 66160, United States
St Louis, Missouri 63132, United States
Marseille, 13385, France
Rome, 00185, Italy
Torino, 10126, Italy
Kragujevac, 34 000, Serbia
Oleksandrivka, Odesa Oblast 67513, Ukraine
Dnipro, 49005, Ukraine
Kharkiv, 61068, Ukraine
Kharkiv, 61068, Ukraine
Odesa, 65006, Ukraine
Vinnytsia, 21005, Ukraine
Zaporizhzhya, 69600, Ukraine
Bath, BA1 3NG, United Kingdom